Evolent Health, INC Form 4 insider transactions

Evolent Health CEO Seth Blackley reported transactions involving restricted stock units and common stock, including a significant grant of RSUs.

Evolent Health's General Counsel, Jonathan Weinberg, reported transactions involving restricted stock units and common stock, including shares withheld for tax obligations.

Evolent Health's President, Daniel Joseph McCarthy, reported transactions involving Class A Common Stock, including the acquisition of restricted stock units and the withholding of shares for tax obligations.

Evolent Health, Inc. reports that Chief Accounting Officer Shams Aammaad was granted 28,790 restricted stock units under the company's 2015 Omnibus Incentive Compensation Plan.

Evolent Health Director Toyin Ajayi acquired 41,096 shares of Class A Common Stock through restricted stock units.

Evolent Health Director Russell Monroe Glass acquired 41,096 shares of Class A Common Stock through a restricted stock unit grant.

Evolent Health Director Peter J. Grua acquired 41,096 shares of Class A Common Stock through restricted stock units, increasing his beneficial ownership.

Evolent Health Director Shawn M. Guertin acquired 41,096 shares of Class A Common Stock through a restricted stock unit grant.

Richard M. Jelinek, a Director at Evolent Health, Inc., acquired 41,096 shares of Class A Common Stock on June 4, 2026, as part of a restricted stock unit grant.

Evolent Health Director Kim Keck acquired 41,096 shares of Class A Common Stock through a restricted stock unit grant.

Evolent Health Director Jill D. Smith reported a transaction involving Class A Common Stock, acquiring 41,096 shares under an incentive plan.

Brendan B. Springstubb, a Director at Evolent Health, Inc., acquired 41,096 shares of Class A Common Stock through a restricted stock unit grant.

Evolent Health Director Craig A. Barbarosh acquired 41,096 shares of Class A Common Stock through restricted stock units.

Evolent Health CEO Seth Blackley reported recent acquisitions of common stock from PSU settlements and new PSU grants, alongside tax-related share disposals.

Evolent Health's General Counsel, Jonathan Weinberg, reported a series of equity transactions including RSU vesting, PSU settlement, and a new PSU grant.

Evolent Health's President, Daniel Joseph McCarthy, reported significant equity transactions including the settlement of performance-based share units and a new large PSU grant.

Evolent Health's Chief Accounting Officer, Aammaad Shams, reported share acquisitions from performance-based units and tax-related dispositions.

Evolent Health's Chief Financial Officer, Mario Ramos, was granted 429,041 performance-based share units tied to future stock price performance and service conditions.

Evolent Health, Inc. Director Jill D. Smith was granted 23,137 restricted stock units as part of her compensation.

Evolent Health's Chief Financial Officer, Mario Ramos, was granted 587,500 restricted stock units as an employment inducement award.

Evolent Health Director Brendan B. Springstubb acquired 10,000 shares of Class A Common Stock at $3.8199 per share, increasing his direct beneficial ownership to 58,821 shares.

Evolent Health's Chief Accounting Officer, Aammaad Shams, disposed of 2,567 shares of Class A Common Stock to cover tax obligations related to restricted stock unit vesting.

Evolent Health, Inc. CEO Seth Blackley was granted 67,150 restricted stock units on July 1, 2025, as part of the company's annual incentive compensation plan, following shareholder approval.

Evolent Health, Inc. General Counsel Jonathan Weinberg was granted 23,394 Class A Common Stock restricted stock units as part of the company's annual incentive compensation plan.

Evolent Health, Inc. President Daniel Joseph McCarthy was granted 44,767 restricted stock units as part of the company's annual compensation cycle, aligning executive incentives with shareholder interests.

Evolent Health's Chief Financial Officer, John Paul Johnson, was granted 25,461 restricted stock units as part of the company's annual incentive compensation plan, vesting over three years.

Evolent Health, Inc. (EVH) Director Shawn M. Guertin has been granted 21,979 restricted stock units (RSUs) as part of the company's incentive compensation plan.

Evolent Health, Inc. Director Richard M. Jelinek has been granted 21,979 restricted stock units, aligning his interests with shareholders.

Evolent Health, Inc. Director Cheryl Scott was granted 21,979 restricted stock units (RSUs) on June 5, 2025, aligning her interests with shareholder value.

Evolent Health, Inc. Director Brendan Springstubb was granted 21,979 restricted stock units on June 5, 2025, as part of the company's incentive compensation plan.